MedTrace Logo

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT02243358 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-27

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.

Conditions

  • Pancreas Neoplasm Malignant Resectable

Interventions

DRUG

Folfox6

DRUG

Gemcitabine

RADIATION

Radiation Therapy

PROCEDURE

Pancreaticoduodenectomy with retroperitoneal lymphadenectomy

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Gazala Khan, MD · Henry Ford Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2017-06-28
Completion
2020-01-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02243358 on ClinicalTrials.gov